Prefilled Syringes Market worth $8.6 billion by 2025 - Rising targeted disease population

The Research Report on "Prefilled Syringes Market by Type [Conventional (Disposable, Reusable), Safety], Material (Glass, Plastic), Design (Single-Chamber, Dual-Chamber, Customized), Application (Diabetes, Cancer, Arthritis, Anaphylaxis, Ophthalmology) - Global Forecast to 2025", is estimated to be USD 5.6 billion in 2020 and projected to reach USD 8.6 billion by 2025, at a CAGR of 9.0%.

Growth Driver: Rising target disease population;

Prefilled syringes are mainly used for the treatment of chronic conditions, such as heart diseases, diabetes, and autoimmune diseases, which require patients to self-administer medications. As a result, the increasing incidence and prevalence of chronic and lifestyle diseases across the globe is a major factor contributing to the growth of the prefilled syringes market. Moreover, there is a growing demand for self-injection devices, considering the convenience and safety associated with their use.

Following are some of the key statistics related to the growing incidence and prevalence of chronic diseases:

- Globally, in 2019, approximately 436 million adults (prevalence 9.3%) were suffering from diabetes, and it is expected to rise to 700 million (prevalence 10.9%) by 2045. Moreover, more than 1.1 million children and adolescents are living with type 1 diabetes (Source: International Diabetes Federation)

- In 2018, total number of cancer cases globally was recorded at 18 million. Most common cases being lung, breast, cancer with incidence rate in double digits (Source: WHO)

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=16618331

Industry Segmentation In Detailed:

Increasing adoption of self-administered injectable drugs is expected to result in the segment occupying the majority of the market share

The conventional prefilled syringes market is estimated to have the largest market share by value. Growth of this segment can be attributed to the the advantages offered, such as safe administration, ease of use for both healthcare professionals and end users, reduced risk of contamination of the product, less waste of costly API, ease of manufacturing, improved dosing accuracy, and enhanced product differentiation when compared to vials is expected to drive the market growth

Plastic Prefilled Syringes estimated to be the fastest-growing market

Plastic prefilled syringes are estimated to be the fastest-growing segment in the prefilled syringes market. The growth of this segment can be attributed to the rising development of newer polymers (which possess various physical and chemical properties such as high heat & break resistance, tolerance of freeze-drying & liquid nitrogen exposure, high transparency, and solvent resistance.

Europe is estimated to be the largest market due to the rising prevalence of chronic diseases, growth of the biologics and biosimilars market, technological advancements, geographical expansion by key manufacturers, aging population, and high adoption of self-injection devices are driving the demand for self-injectable prefilled syringes.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=16618331

Leading Key Players and Analysis:

Becton, Dickinson and Company (US), Gerresheimer (Germany), SCHOTT AG (Germany), and West Pharmaceutical Services, Inc. (US) are the key players in the global prefilled syringes market.

Gerresheimer (Germany) held the second position in the global prefilled syringes market, with a share of 13.3% in 2019. The company's customer base includes a large number of global blue chip pharmaceutical and healthcare companies (Sanofi, Bayer, AstraZeneca, Novo Nordisk, Johnson & Johnson, and Novartis). To maintain its position in the market, the company focuses on the strategies of product launches and partnerships.

Geographical Analysis in Detailed:

The Europe is one of the major revenue-generating regions in the prefilled syringes market. Rising prevalence of chronic diseases, growth of the biologics and biosimilars market, technological advancements, geographical expansion by key manufacturers, aging population, and high adoption of self-injection devices are driving the demand for self-injectable prefilled syringes. are the major factors driving the growth of the syringes market in Europe.

Speak to Analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=16618331

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
sales@marketsandmarkets.com

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model - GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets's flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

This release was published on openPR.